Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen

Establishment of an uniform and effective vaccine development strategy is critical to conquering current and emerging infectious diseases. Despite successes against a range of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and need adjuvants that frequently have limited efficacy and/or poisonous side effects. As a consequence, vaccine discovery is often slow, inefficient, and ineffective in the case of many high priority pathogens. The current revelation indicates that vaccine generation for bacterial pathogens could be improved by optimizing the efficacy of processing/presentation of an agricultural immunogen via the targeting of immunogen into CR2 or TLR2 on APCs. This strategy not only yields an adjuvant-free mucosal vaccine from a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly affecting preventative medicine/public wellbeing.


To view all patent detail click here





Francisella tularensis (Ft)) is a Gram-negative, facultative intra-cellular pathogen and the etiological agent of tularemia, a disease that could be fatal in humans. Ft can infect people at both mucosal and peripheral sites, with all the formerbeing the most deadly kind of infection. Both humoral and cellular immunity play a role in protection from this organism. While there are only about 200 known Ft infections each year in the U.S., as few as one organism could be fatal, if inhaled. Thishas contributed to the apparent concern that Ft could be utilized as a bioterrorism agent, when spread as an aerosol in a populated place. Therefore, Ft has been recorded as a category A select agent, and there’s strong interest in the growth of an effectivevaccine against Ft.

Furthermore, the evolution of needle-free, mucosal vaccines which don’t require exogenous adjuvants is of significant interest to all aspects of infectious disease including biodefense. Though some infections can be treated successfullywith antibiotics, under some conditions, such as biodefense, vaccination is favored over post-exposure therapy.

Thus far, the current gold standard for tularemia prophylaxis, infection with viable Live Vaccine Strain (LVS) Ft, provides only moderate protection from humans. Thusa need exists for a vaccine that yields enhanced efficacy and a major effort isunderway to come up with a new generation of safe and effective vaccines against the disease.

IP reviewed by Plant-Grow agriculture technology news